CVS Health's Comeback Is Just Getting Started -- and Its Valuation Still Looks Shockingly Cheap

CVS Health reported first-quarter revenue of $100.4 billion, up about 6% year over year, and adjusted EPS of $2.57, up about 14%, both ahead of analyst estimates. The company also raised its EPS guidance for fiscal 2026 as its medical benefit ratio fell to 84.6% from the prior-year period, reflecting improving insurance profitability and better cost control. Long-term support comes from its diversified healthcare platform, 2.6% forward dividend yield, and valuation at 13.8x forward earnings versus 17.4x for the healthcare sector.

Analysis

CVS is starting to look less like a busted turnaround and more like a self-help story with operating leverage. The key market implication is that incremental improvement in medical cost discipline should flow disproportionately to earnings because the valuation is still anchored to a low-expectation multiple; that creates room for further rerating if management can string together a few more clean quarters. In other words, this is no longer just a mean-reversion trade on sentiment — it is a duration trade on execution.

The bigger second-order effect is competitive. If CVS keeps tightening utilization and steering more care through lower-cost channels, it can force a response from peers across managed care and retail pharmacy, especially those with weaker vertical integration. That pressure should widen the gap between integrated platforms that can monetize data, pharmacy, and care delivery together versus pure-play insurers that remain more exposed to medical trend shocks. The likely winners are the operators with the ability to cross-sell and control downstream spend; the losers are insurers with thinner underwriting buffers and less pharmacy leverage.

The consensus risk is that investors may be extrapolating one good print into a multi-year improvement path. MA remains the swing factor: even modest deterioration in utilization or pricing can overwhelm the cost savings from digitization, and that risk is highest over the next 2-3 quarters rather than the next several years. The market is also underestimating how much of the upside can already be in the stock after a 48% run; if guidance merely meets, the multiple can stall even if fundamentals continue to improve.

Contrarianly, the dividend and valuation screen may be masking a quality problem: cheap healthcare names often stay cheap when earnings visibility is still hostage to insurance cycle volatility. The cleaner expression may not be outright long CVS, but a relative value bet that the company can outperform weaker diversified healthcare names as the next few quarters prove out the reset. If management reaffirms guidance with another beat, the stock can keep grinding higher; if MBR ticks back up, the downside will likely be abrupt because the market has started to price in durability.

Key Decisions for Investors

• Long CVS into the next 1-2 earnings prints, but size as a tactical position rather than a core hold; upside is continued rerating if margin discipline holds, while downside is a quick de-rating if MA costs reaccelerate.
• Use a CVS vs. managed-care basket pair trade: long CVS / short a weaker insurer exposure over 3-6 months to isolate relative operating improvement from sector beta.
• Sell cash-secured puts or use a put spread in CVS for the next earnings cycle if you want to express cautious bullishness; the setup favors premium capture as long as guidance remains intact.
• Take partial profits on existing CVS longs after the recent run and re-add only on either a post-earnings pullback or a confirmed upward revision cycle; the risk/reward is less attractive after the 48% move.
• Avoid chasing CVS versus higher-quality healthcare compounders unless the next quarter confirms that the MBR improvement is structural, not just timing; the trade only works if execution is repeatable.